1. Home
  2. WRD vs IRD Comparison

WRD vs IRD Comparison

Compare WRD & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WRD
  • IRD
  • Stock Information
  • Founded
  • WRD 2017
  • IRD 2018
  • Country
  • WRD China
  • IRD United States
  • Employees
  • WRD N/A
  • IRD N/A
  • Industry
  • WRD
  • IRD
  • Sector
  • WRD
  • IRD
  • Exchange
  • WRD NYSE
  • IRD NYSE
  • Market Cap
  • WRD 2.8B
  • IRD 59.1M
  • IPO Year
  • WRD 2024
  • IRD N/A
  • Fundamental
  • Price
  • WRD $8.62
  • IRD $1.13
  • Analyst Decision
  • WRD Buy
  • IRD Strong Buy
  • Analyst Count
  • WRD 2
  • IRD 3
  • Target Price
  • WRD $22.00
  • IRD $6.33
  • AVG Volume (30 Days)
  • WRD 7.7M
  • IRD 752.8K
  • Earning Date
  • WRD 08-25-2025
  • IRD 08-15-2025
  • Dividend Yield
  • WRD N/A
  • IRD N/A
  • EPS Growth
  • WRD N/A
  • IRD N/A
  • EPS
  • WRD N/A
  • IRD N/A
  • Revenue
  • WRD $49,940,881.00
  • IRD $13,651,000.00
  • Revenue This Year
  • WRD N/A
  • IRD $51.41
  • Revenue Next Year
  • WRD $218.93
  • IRD $68.84
  • P/E Ratio
  • WRD N/A
  • IRD N/A
  • Revenue Growth
  • WRD N/A
  • IRD N/A
  • 52 Week Low
  • WRD $6.03
  • IRD $0.65
  • 52 Week High
  • WRD $44.00
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • WRD N/A
  • IRD N/A
  • Support Level
  • WRD N/A
  • IRD N/A
  • Resistance Level
  • WRD N/A
  • IRD N/A
  • Average True Range (ATR)
  • WRD 0.00
  • IRD 0.00
  • MACD
  • WRD 0.00
  • IRD 0.00
  • Stochastic Oscillator
  • WRD 0.00
  • IRD 0.00

About WRD WERIDE INC. SPON ADS EACH REP 3 CL A ORD SHS

WeRide Inc operates in the autonomous driving industry. The company has developed a universal autonomous driving technology platform that integrates full-stack software algorithms, modularized hardware solutions, and a cloud-based infrastructure platform. The company provides autonomous driving products and services from L2 to L4 vehicles. The products of the company includes Robotaxi, Robobus, Robovan, Robosweeper, and others. The company earns its revenue from the People's Republic of China.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: